Trials / Completed
CompletedNCT01893099
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Centre Hospitalier Universitaire Vaudois · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The best way to combine a loco-regional procedure such as chemoembolisation or radioembolization combined with an anti-angiogenic drug is not clear. This phase I trial aims to establish, first, the tolerability of the combination of liver radioembolization with SirSpheres® and sorafenib in uveal melanoma patients with liver metastasis studying different schedules of administration of sorafenib after and before radioembolization. Secondly, we aim to evaluate angiogenic markers modifications during these different schedules, either in the serum or radiologicaly. Dose of Sorafenib will be 400 mg BID and the timing of introduction will differ for one cohort to the other, given after the radioembolization for initials cohorts and finally, before and concomitantly to radioembolization for the last cohort.
Detailed description
Primary objective: To evaluate the safety and tolerability of sorafenib in combination with SIR-Spheres® radioembolization in uveal melanoma patients metastatic to the liver. Secondary objectives: * Translational research on biomarkers (blood and liver biopsies) as well as on radiological exam by using microbubble contrast enhanced ultrasound. Angiogenic markers such as VEGF, IGF-2, TFG Angiopoietin-2 and IL-8 will be monitored. Correlations will be investigated between the angiogenic markers (blood \& tumor tissue), angiogenic radiological exam and the response to the treatment. * To evaluate the response, clinical benefit, PFS and survival of the patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance. |
| DEVICE | Radioembolization with SIR-Spheres® (Yttrium Microspheres) |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2017-11-28
- Completion
- 2017-11-28
- First posted
- 2013-07-08
- Last updated
- 2018-04-23
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01893099. Inclusion in this directory is not an endorsement.